

EDMA Workshop: IVD industry's view of HTA in the context of market access

02 June 2015, 10h00-17h00

*EDMA OFFICES
Rue Joseph II 40, 1000 Brussels*

THIS WORKSHOP IS FREE OF CHARGE AND OPEN TO:

- EDMA Corporate Associate Members (CAMs)
- IVD industry members and staff of the National Association Members (NAMs) affiliated to EDMA

The value of IVDs is not always recognized at the funding and reimbursement level in Europe, with a dual system of local decisions on funding, reimbursement and use of innovation, generally not linked to value considerations for allocation of resources; and EU HTA cooperation focusing on setting-up processes and tools for innovation to be assessed at EU and national level.

Clear linkage between assessment and real decision making ('reward') for manufacturer's who undergo HTA is still lacking.

EDMA has achieved a position in relation to the value of HTA and HTA cooperation for IVD industry, and believes that the European HTA Cooperation needs to be of value for decision-makers and other stakeholders and a timely dialogue involving manufacturers should be an integral part of the HTA process.

IVD manufacturers think that if an HTA on IVDs is requested, it should be performed in order to inform a decision point through a "fit-for-purpose" approach linked to a decision about coverage, reimbursement, funding and/or use; and using appropriate and specific methodologies.

This workshop is aimed at sharing information and tools to understand and communicate EDMA's position on HTA in the context of market access for IVDs to a wide range of target audiences.

Agenda (draft)

09:30 **Registration and Coffee**

10:00 **Welcome**
Lisse-Lotte Hermansson (Thermo Fisher) Co-Chair of EDMA HTA TF, Chair of CDx Ad Hoc Group.
Markus Ott (Bayer) Co-Chair of EDMA HTA TF & EDMA Synergy Regulation –HTA TF, Chair of Policy & Value Based Assessment Ad Hoc Group.
Yves Verboven – Director Market Access & Economic Policies, EDMA.

10:15 **Introduction and objectives of workshop**
Victoria Wurcel- EDMA HTA & Economic Policies Manager

10:30 **What is happening with HTA and IVDs? Different perspectives (EU, UK, Germany, France)**
EDMA HTA TF members/NAMs
Yves Verboven (EDMA)
Victoria Wurcel (EDMA)

12:30 **Lunch**

13:30 **Health Technology Assessment for IVDs in the context of market access: how would it be useful? Key points of EDMA's position on HTA.**
Victoria Wurcel (EDMA)

14:30 **Round table: How will EDMA continue to share its view on HTA to make a change?**
Lisse-Lotte Hermansson (Thermo Fisher)
Markus Ott (Bayer)
EDMA HTA TF members

16:45 **Conclusions and closing statements**
Lisse-Lotte Hermansson (Thermo Fisher)
Markus Ott (Bayer)
Yves Verboven (EDMA)

17:00 **End of workshop**
